跳至主要内容
临床试验/NCT00796913
NCT00796913已完成不适用

Prospective Randomized Study of Therapy Withdrawal vs Continued Low Dose Medical Therapy in Patients With Graves' Disease Entering Remission During ATD Therapy

Aalborg University Hospital0 个研究点目标入组 139 人开始时间: 2008年1月7日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
139
主要终点
Relapse of hyperthyroidism

研究概览

简要总结

ATD therapy for Graves' disease is one of the commonly used options for therapy of the hyperthyroidism. The investigators study how to optimally keep patients in remission.

详细描述

A detailed description of patients entering the initial observational phase of the study (RISG1) has been published:

Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Pedersen IB, Andersen SL. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study. J Thyroid Res. 2014;2014:165487. doi: 10.1155/2014/165487.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Graves hyperthyroidism in remission after ATD

排除标准

  • Age < 18, severe concomitant disease

结局指标

主要结局

Relapse of hyperthyroidism

时间窗: 2 years

次要结局

  • Reoccurrence of TSH-receptor autoimmunity(2 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jesper Scott Karmisholt

MD

Aalborg University Hospital

相似试验